Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,917 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Atrial Fibrillation, Hypertension
Interventions: catheter ablation, renal sympathetic denervation; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Short Hills, New Jersey

Conditions: Cardiac Surgery
Interventions: Intervention, Standard of Care BP management; Diagnostic Test · Other
Lead sponsor: Parthasarathy Thirumala; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Metabolic Syndrome, Hypertension, Chronic Disease
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 28,813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Chinle, Arizona • Fort Defiance, Arizona • Kayenta, Arizona + 3 more

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: LIQ861 (treprostinil) inhalation powder; Combination Product
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Georgia

Conditions: Hypertension
Interventions: Telmisartan & Hydrochlorothiazide, Losartan & Hydrochlorothiazide, ABPM; Drug · Procedure
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 69
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Carmichael, California + 57 more

Conditions: Resistant Hypertension
Interventions: CIN-107, Placebo; Drug
Lead sponsor: CinCor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 80
States / cities: Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: QGC001; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Interventions: Guide My Care Tool; Other
Lead sponsor: Fitbit LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glaucoma
Interventions: Glaucoma Diagnosis, Name: Neucodia; Device
Lead sponsor: Synabridge Corporation; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • New Haven, Connecticut • Raritan, New Jersey + 2 more

Conditions: Pulmonary Hypertension
Interventions: UT-15C; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 5 more

Conditions: Visual Field Defect, Peripheral, Glaucoma, Open-Angle
Interventions: Vitamin B3, Pyruvate, Placebo; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Hypertension
Interventions: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertension and Hyperlipidemia
Interventions: HTN and Medication Adherence; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: EngageRx_SMBP; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cataract, IOL, Glaucoma, Open-Angle
Interventions: Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold; Procedure
Lead sponsor: Vold Vision P.L.L.C; Other
Eligibility: 45 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Diastolic Dysfunction, Hypertension
Interventions: Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years and older
Enrollment: 317 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Glaucoma, Ocular Hypertension
Interventions: BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Week to 5 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Preeclampsia, Fetal Growth Restriction
Interventions: Not listed
Lead sponsor: Fetal Medicine Foundation; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Type 2 Diabetes, High Blood Pressure
Interventions: Polypill, Combined prescription of the individual medications; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Pre-hypertension
Interventions: Sleep extension; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

IMMPRES: Intraoperative Monitoring & Management to Reduce Stroke

Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

Care COMPASS Study

Instrument for Glaucoma Early Detection and Monitoring

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Adjunctive Study of AL-37807 Ophthalmic Suspension

Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

Gamification and Medication Adherence (GAME Adherence)

EngageRx With Integrated Self-Measurement of Blood Pressure

Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

First Trimester Prediction of Preeclampsia and Fetal Growth Restriction

Polypill for Prevention of Cardiomyopathy

Restoring Sleep Homeostasis to Lower Blood Pressure